Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol

European Journal of Dermatology

Volumn 13, Issue 1, 2003, Pages 40-43

  Momeni, Ali Z ^a   Aminjavaheri, Malihalsadat ^a  

^a Aminjavaheri Medical Lab   (Iran)

Author keywords

Allopurinol; Leishmaniasis; Meglumine antimoniate; Non healing leishmaniasis

Indexed keywords

ALLOPURINOL; MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HUMAN; IRAN; MALE; RECURRENT DISEASE; SKIN LEISHMANIASIS; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; ALLOPURINOL; ANTIMONY; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 0037286073     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Azmoudeh M. Report on leishmaniasis in Iran. Islamic Republic of Iran, Ministry of Health. Treatment and Medication Educotion, 1990.
2. Nadim A, Mesghali A, Amini H. Epidemiology of cutaneous leishmaniasis in Isfahan. Iran. III. The Vector. Trans R Soc Trop Med Hyg 1971; 62: 543-8.
3. Nadim A, Seyedi rashti MA. Brief review of the epidemiology of various type of leishmaniasis in Iran. Acta Med Iran 1971; 99: 106-10.
4. Grevelink SA, Lcrner EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-62.
5. Weinrauch L. EL-on J. Current therapy af cutaneous leishmaniasis. Int J Dermatal 1987; 9: 564-70.
6. Mameni AZ, Yotsumoto S, Mehregan D, Mehregan AH, et al. Chronic lupoid leishmaniasis. Arch Dermatal 1996; 132: 198-220.
7. Martinez S, Marr JJ. Allopurinol in the treatment of american cutaneous leishmaniasis. NEJM 1992; 326: 741-4.
8. Nadim A, Javadian E. Leishmanization in the Islomic Republic af Iran. In: Waltan BC, Wijeyoratne PM, Modabber F, eds. Research on cantrol strategies for leishmaniasis. Ottawa: IDRC, 1988: 338-39.
9. Heung-Chong BA. Oriental sore; a look at trends in and appraach to the treatment of leishmaniasis. Int J Dermatol 1986; 25: 615-22.
10. Bryeeson A. Immunological aspects of clinical leishmaniasis. Proc R Soc Med 1970; 63: 1056-60.
11. Momeni AZ, Aminjavaheri M. Clinical picture of cutaneaus leishmaniasis in Isfahan Iran. Int J Dermatol 1994; 33: 260-5.
12. Roberts WL, Berman JD, Rainey PM. In vitro antileshmanial properties of tri-and pentavalent antimanial preparations. Ant Mic Agen Chemo 1995; 39: 1234-9.
13. Olliaro PL, Brycesan ADM. Practical progress and new drugs far changing patterns of leishmaniasis. Parasit Today 1993; 9: 323-8.
14. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans P Soc Trop Med Hyg 1985; 79: 715-8.
15. Koger PA, Rees PH, Wellde BT, et al. Allopurinol in the treatment of visceral leishmoniasis. Trans F Soc Trop Med Hyg 1981; 75: 556-9.
16. Jha TK. Evaluation of allopurinol in the treatment of kala-azar occurring in north Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 204-7.
17. Senz RE, Paz HM, Johnson CM. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Inf Dis 1989; 160: 153-8.